Skip to main content
Caplight Logo









Umlaut.bio GmbH

Umlaut.bio GmbH

Private
HeidelbergHealthcare & Life Scienceshttps://umlaut.bio/

Last Round

Pre Seed

Feb 19, 2026

Total Funding Raised

$3.54M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Umlaut.bio GmbH is a biotechnology company that develops first-in-biology small molecule therapeutics targeting tRNA modifications to treat cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

tRNA modificationsmall molecule therapeuticsdrug discoveryepitranscriptomicsrna therapeuticsoncologyrna drug discoveryimmunologyprecision medicinehigh-throughput screeningmass spectrometrypreclinical biotechtarget discoverydrug pipelinebiotech spin-off

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Umlaut.bio GmbH Comparables

Compare Umlaut.bio GmbH with similar companies based on industry and business-model similarity.

Umlaut.bio GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Chemestmed
84%
O2nix Bio
79%
Twentyeight-Seven Therapeutics
77%

Umlaut.bio GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedFeb 19, 2026

Umlaut.bio GmbH Investors

Notable investors and investment history

Umlaut.bio GmbH investors
InvestorRounds
BaseLaunchPre Seed
High-Tech GründerfondsPre Seed
L-BankPre Seed
LBBW Venture CapitalPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors grew 3965% MoM, reaching 1.1K.

  • Apr 3, 2026

    Monthly visitors grew 11300% MoM, from 26 to 3K.

Umlaut.bio GmbH Filings

Explore SEC and related filing metadata, where available.

Umlaut.bio GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Umlaut.bio GmbH's valuation, stock price, and market status.

Is Umlaut.bio GmbH a public or private company?

Umlaut.bio GmbH is a private company.

What is the current stock price of Umlaut.bio GmbH?

Umlaut.bio GmbH is a private company with no public stock price. Caplight tracks Umlaut.bio GmbH's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Umlaut.bio GmbH worth (valuation)?

Valuation information for Umlaut.bio GmbH is not publicly available.

Can I buy Umlaut.bio GmbH stock?

Umlaut.bio GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Umlaut.bio GmbH's last funding round?

Umlaut.bio GmbH's most recent funding round was Pre Seed on February 19, 2026.

Who are the main investors in Umlaut.bio GmbH?

Key investors in Umlaut.bio GmbH include BaseLaunch, High-Tech Gründerfonds, L-Bank, LBBW Venture Capital.

Will Umlaut.bio GmbH IPO soon?

No public IPO plans have been announced for Umlaut.bio GmbH.

How can I track Umlaut.bio GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Umlaut.bio GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHeidelberg
Employee Range3
Year Founded2024
Last FundingFeb 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?